UBS AM’s Meridian Bioscience Inc VIVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-53,786
| Closed | -$1.7M | – | 2790 |
|
|
2022
Q3 | $1.7M | Buy |
53,786
+14,284
| +36% | +$463K | ﹤0.01% | 1688 |
|
|
2022
Q2 | $1.2M | Hold |
39,502
| – | – | ﹤0.01% | 1860 |
|
|
2022
Q1 | $1.03M | Sell |
39,502
-12,160
| -24% | -$289K | ﹤0.01% | 2124 |
|
|
2021
Q4 | $1.05M | Hold |
51,662
| – | – | ﹤0.01% | 2189 |
|
|
2021
Q3 | $994K | Sell |
51,662
-3,765
| -7% | -$75K | ﹤0.01% | 2166 |
|
|
2021
Q2 | $1.23M | Buy |
55,427
+4,697
| +9% | +$99.6K | ﹤0.01% | 2101 |
|
|
2021
Q1 | $1.33M | Buy |
50,730
+2,268
| +5% | +$53.9K | ﹤0.01% | 1942 |
|
|
2020
Q4 | $906K | Sell |
48,462
-2,210
| -4% | -$41.3K | ﹤0.01% | 2042 |
|
|
2020
Q3 | $860K | Buy |
50,672
+3,896
| +8% | +$75.7K | ﹤0.01% | 1903 |
|
|
2020
Q2 | $1.09M | Sell |
46,776
-2,864
| -6% | -$41.5K | ﹤0.01% | 1759 |
|
|
2020
Q1 | $417K | Buy |
49,640
+11,080
| +29% | +$93.3K | ﹤0.01% | 2043 |
|
|
2019
Q4 | $377K | Sell |
38,560
-8,757
| -19% | -$82.2K | ﹤0.01% | 2322 |
|
|
2019
Q3 | $449K | Buy |
47,317
+18,787
| +66% | +$198K | ﹤0.01% | 2336 |
|
|
2019
Q2 | $339K | Buy |
28,530
+1,163
| +4% | +$14K | ﹤0.01% | 2370 |
|
|
2019
Q1 | $482K | Buy |
27,367
+1,300
| +5% | +$21.6K | ﹤0.01% | 2123 |
|
|
2018
Q4 | $453K | Buy |
26,067
+2,857
| +12% | +$48.7K | ﹤0.01% | 2040 |
|
|
2018
Q3 | $346K | Hold |
23,210
| – | – | ﹤0.01% | 2234 |
|
|
2018
Q2 | $369K | Hold |
23,210
| – | – | ﹤0.01% | 2224 |
|
|
2018
Q1 | $330K | Hold |
23,210
| – | – | ﹤0.01% | 2171 |
|
|
2017
Q4 | $325K | Hold |
23,210
| – | – | ﹤0.01% | 2095 |
|
|
2017
Q3 | $332K | Buy |
23,210
+10,119
| +77% | +$145K | ﹤0.01% | 2054 |
|
|
2017
Q2 | $206K | Buy |
13,091
+92
| +0.7% | +$1.32K | ﹤0.01% | 2211 |
|
|
2017
Q1 | $179K | Buy |
+12,999
| New | +$182K | ﹤0.01% | 2216 |
|
|
2016
Q4 | – | Sell |
-19,099
| Closed | -$368K | – | 2718 |
|
|
2016
Q3 | $368K | Hold |
19,099
| – | – | ﹤0.01% | 2157 |
|
|
2016
Q2 | $372K | Buy |
19,099
+3,200
| +20% | +$62.8K | ﹤0.01% | 2122 |
|
|
2016
Q1 | $328K | Sell |
15,899
-2,100
| -12% | -$41.4K | ﹤0.01% | 2160 |
|
|
2015
Q4 | $369K | Sell |
17,999
-194,386
| -92% | -$3.73M | ﹤0.01% | 2228 |
|
|
2015
Q3 | $3.63M | Buy |
212,385
+102,597
| +93% | +$1.88M | ﹤0.01% | 1169 |
|
|
2015
Q2 | $2.05M | Buy |
109,788
+93,389
| +569% | +$1.73M | ﹤0.01% | 1397 |
|
|
2015
Q1 | $313K | Buy |
16,399
+1,100
| +7% | +$20.3K | ﹤0.01% | 2235 |
|
|
2014
Q4 | $252K | Hold |
15,299
| – | – | ﹤0.01% | 2338 |
|
|
2014
Q3 | $271K | Hold |
15,299
| – | – | ﹤0.01% | 2208 |
|
|
2014
Q2 | $316K | Hold |
15,299
| – | – | ﹤0.01% | 2152 |
|
|
2014
Q1 | $333K | Buy |
15,299
+1,300
| +9% | +$29.8K | ﹤0.01% | 2114 |
|
|
2013
Q4 | $371K | Sell |
13,999
-1,100
| -7% | -$27K | ﹤0.01% | 1984 |
|
|
2013
Q3 | $357K | Hold |
15,099
| – | – | ﹤0.01% | 1970 |
|
|
2013
Q2 | $325K | Buy |
+15,099
| New | +$326K | ﹤0.01% | 1947 |
|
Other funds holding VIVO
MF
NAM
UBS AM's VIVO Position: Q4 2022 in Review
UBS AM sold out of Meridian Bioscience Inc (VIVO) in Q4 2022, closing a stake of 53,786 shares — an estimated $1.7M sold.
UBS AM first reported a position in VIVO in Q2 2013 and held it in 37 quarters. The position peaked at $3.63M in Q3 2015. 218 funds tracked by Wall St. Rank hold VIVO as of Q4 2022.
- UBS AM reported no remaining Meridian Bioscience Inc position as of Q4 2022 after selling out during the quarter.
- UBS AM sold 53,786 Meridian Bioscience Inc shares in Q4 2022, an estimated $1.7M.
- UBS AM first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 37 quarters.
- UBS AM's Meridian Bioscience Inc position peaked at $3.63M in Q3 2015.
- 218 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2022.
Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.